Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MESO message board posts where the ticker symbol MESO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

Related news from
Thu, 21 Jun 2018
13:28:00 +0000
Mesoblast Soars on Stem-Cell Treatment Data
The Australian company unveiled data from a study evaluating a potential treatment for children with steroid refractory acute Graft Versus Host Disease.
Thu, 21 Jun 2018
10:00:00 +0000
Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting
NEW YORK and MELBOURNE, Australia, June 21, 2018-- Mesoblast Limited today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, ...
Tue, 19 Jun 2018
10:00:00 +0000
U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board
Mesoblast Limited (MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO for major U.S. healthcare organizations. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado’s Centura Health.
Wed, 06 Jun 2018
11:30:00 +0000
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group — Discovering Underlying Factors of Influence
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mesoblast ...
Wed, 30 May 2018
23:32:40 +0000
Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018
MELBOURNE, Australia and NEW YORK, May 30, 2018-- Mesoblast Limited today announced strong financial results for the nine months ended March 31, 2018 and provided operational highlights for the third quarter ...
Wed, 30 May 2018
22:41:56 +0000
Mesoblast Appoints New Chief Financial Officer
Mesoblast Limited (ASX:MSB) (MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York. Chief Executive Dr Silviu Itescu welcomed the appointment of Mr Muntner stating he would bring substantial U.S. corporate finance, transactional and capital markets experience to Mesoblast. Mr Muntner has accrued 20 years’ experience in healthcare investment banking and corporate finance, and has been involved in a wide range of healthcare-related transactions with approximately $11 billion in value.
Tue, 29 May 2018
19:21:43 +0000
Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018
NEW YORK and MELBOURNE, Australia, May 29, 2018-- Mesoblast Limited will report financial results for the quarter ended March 31, 2018 in a webcast beginning at 6:30 pm on Wednesday, May 30, 2018 EST; ...
Tue, 29 May 2018
10:00:00 +0000
Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cell-based Immunotherapies for Solid Cancers
Mesoblast Limited (MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies.
Tue, 08 May 2018
10:00:00 +0000
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting
Mesoblast Limited (MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel-L) in children with steroid-refractory acute Graft versus Host Disease (aGVHD) were presented at the 2018 International Society for Cell and Gene Therapy (ISCT) plenary breakout session held in Boston last week. Dr Kurtzberg described the properties of remestemcel-L that are relevant to understanding proposed mechanisms of action (MOA) in aGVHD, including sensing of damaging inflammatory mediators and consequent reduction in activation of immune cells.
Tue, 01 May 2018
10:00:00 +0000
Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference
NEW YORK and MELBOURNE, Australia, May 01, 2018-- Mesoblast’ s proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican Conference on global healthcare ...
Mon, 23 Apr 2018
20:26:40 +0000
Who Just Ramped Up Their Shares In Mesoblast Limited (ASX:MSB)?
Mesoblast Limited develops cell-based medicines. Mesoblast is one of Australia’s small-cap stocks that saw some insider buying over the past three months, with insiders investing in more than 15 millionRead More...
Fri, 20 Apr 2018
11:20:00 +0000
Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure
Stock Monitor: Caladrius Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Mesoblast Ltd (NASDAQ: MESO ). If ...
Wed, 18 Apr 2018
10:00:00 +0000
Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure
NEW YORK and MELBOURNE, Australia, April 18, 2018-- Mesoblast Limited today provided an update on the Phase 3 and Phase 2 b clinical trials of the Company's proprietary allogeneic mesenchymal precursor ...
Wed, 11 Apr 2018
12:15:00 +0000
Investor Expectations to Drive Momentum within Xcerra, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, WAVE Life Sciences, Hoegh LNG Partners LP, Mesoblast, and Intuitive Surgical — Discovering Underlying Factors of Influence
NEW YORK, April 11, 2018--. In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Sat, 31 Mar 2018
00:15:10 +0000
Market Sentiment Around Loss-Making Mesoblast Limited (ASX:MSB)
Mesoblast Limited’s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.81M and a trailing-twelve month of -US$30.28M, the AU$699.91M market-cap alleviates its loss by movingRead More...
Wed, 28 Mar 2018
22:25:11 +0000
Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
NEW YORK and MELBOURNE, Australia, March 28, 2018-- Mesoblast Limited today announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal injection of its proprietary allogeneic ...
Thu, 22 Mar 2018
16:18:50 +0000
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish
Mesoblast limited (ADR) (NASDAQ: MESO ), a developer of adult stem cell-based products, has struggled to meet key clinical timelines and lost a key partnership with  Teva Pharmaceutical Industries Ltd ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF has been a blessing to me and my family. Even if you are not a big contributor, the information is there for you to read. It is amazing that the fine members of VF will openly help and provide ideas to enhance each others investing." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards